InvestorsHub Logo
Followers 5
Posts 167
Boards Moderated 0
Alias Born 04/05/2012

Re: None

Wednesday, 03/08/2017 9:14:00 AM

Wednesday, March 08, 2017 9:14:00 AM

Post# of 403025
Great news on Brilacidin UPS. 50% Complete Response and 50% Partial Response... and this with sub-optimal formulation. Think what Brilacidin might do once the administration is improved... extending more fully into treating full-blown UC, Chron's. As a comparable, just look at the excitement around Mongersen / GED-301 a few years back, the mega $$$ paid for it. And it hasn't delivered the goods. Latest results showed only 37% of patients achieving a 25% benefit if I recall.

https://doc.research-and-analytics.csfb.com/docView?language=ENG&format=PDF&source_id=csplusresearchcp&document_id=1038573431&serialid=haNEOm2tZKXNkpK%2BdieQP6J6lXEO4jCdohca2L%2FGoYI%3D

In sum: Brilacidin, like Prurisol, seems to be encroaching upon the biologics -- without the side-effects and delivery challenges. Should results continue to pan out, both will be blockbusters.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News